Market Overview

UPDATE: Benchmark Company Initiates Coverage on Varian Medical Systems with Buy Rating, $88 PT

Related VAR
Varian Medical Systems Receives CE Mark for its Latest ProBeam® Proton Therapy System
Varian Inks Licensing Deal with Fraunhofer for Novel Multi-Criteria Optimization (MCO) Tool for Radiotherapy Treatment Planning
Do Not Strike Stryker Out (Seeking Alpha)

In a report published Friday, Benchmark Company initiated coverage on Varian Medical Systems (NYSE: VAR) with a Buy rating and $88.00 price target.

Benchmark noted, “We are initiating coverage of Varian Medical Systems, Inc. (VAR) with a Buy rating and a 12-month price target of $88, or 20 times our fiscal 2014 EPS estimate of $4.42. Based on its historical range, we believe VAR should trade in a range of 15 to 20 times future earnings and, given its world-wide leadership in technology, its backlog, and installed base of customers, our target is based at the top of that range.”

Varian Medical Systems closed on Thursday at $67.74.

Latest Ratings for VAR

Nov 2015CitigroupInitiates Coverage onNeutral
Oct 2015BairdDowngradesOutperformNeutral
Oct 2015JP MorganMaintainsNeutral

View More Analyst Ratings for VAR
View the Latest Analyst Ratings

Posted-In: Benchmark CompanyAnalyst Color Initiation Analyst Ratings


Related Articles (VAR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters